Rencofilstat produces positive outcomes in translational study on idiopathic pulmonary fibrosis

– proteomics analysis showed that rencofilstat improved aberrant protein profiles in ipf tissues – – superior effects of rencofilstat alone and in combination with pirfenidone and nintedanib – edison, n.j., sept. 14, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), fibrotic diseases, hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced positive results from a translational research study in which hepion's lead drug candidate, rencofilstat, was administered to diseased human lung tissue from patients with idiopathic pulmonary fibrosis (“ipf”).
HEPA Ratings Summary
HEPA Quant Ranking